However, CML cells can acquire resistance over the course of TKI treatments due to BCR::ABL mutations that lead to the replacement of amino acids in the ABL tyrosine kinase domain of BCR::ABL; these replacements change the structure of BCR::ABL, preventing TKIs from binding to ABL. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.